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PathogenicityMitochondrial tRNA point mutations are important causes of human disease, and have been associated with a
diverse range of clinical phenotypes. Deﬁnitively proving the pathogenicity of any given mt-tRNA mutation
requires combined molecular, genetic and functional studies. Subsequent evaluation of the mutation using
a pathogenicity scoring system is often very helpful in concluding whether or not the mutation is causing
disease. Despite several independent reports linking the m.3291T>C mutation to disease in humans, albeit
in association with several different phenotypes, its pathogenicity remains controversial. A lack of conclusive
functional evidence and an over-emphasis on the poor evolutionary conservation of the affected nucleotide
have contributed to this controversy. Here we describe an adult patient who presented with deafness and
lipomas and evidence of mitochondrial abnormalities in his muscle biopsy, who harbours the m.3291T>C
mutation, providing conclusive evidence of pathogenicity through analysis of mutation segregation with
cytochrome c oxidase (COX) deﬁciency in single muscle ﬁbres, underlining the importance of performing
functional studies when assessing pathogenicity.
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
Mitochondrial (mt-) tRNA point mutations account for ~50% of all
pathogenic mtDNA mutations despite occupying b10% of the mito-
chondrial genome, emphasising their importance in human pathogen-
esis [1]. Point mutations in the mt-tRNAs have been linked to a host of
mitochondrial disorders and disease phenotypes, with a commonly
poor correlation to genotype. Although point mutations have been
identiﬁed in each of the 22 mt-tRNAs,MTTL1 – the gene encoding for
themt-tRNALeu(UUR) – is a particularlywell-knownhotspot for pathogen-
ic point mutations; most notably the m.3243A>G and m.3271T>C
mutations which are linked to the mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episode (MELAS) syndrome [2–4].
A heteroplasmic m.3291T>C variant in the MTTL1 gene has previ-
ously been reported on 4 separate occasions, in association with
MELAS [2], isolated mild myopathy [5], dementia with hearing loss [6]
and cerebellar ataxia with ophthalmoparesis, hearing loss and myopa-
thy [7]. These reports provided strong evidence linking m.3291T>C to
disease through genetic analysis andmolecular investigations. Crucially
however, all four reports lacked functional evidence of pathogenicityitochondrial Research, Institute
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 license.from either transmitochondrial cybrid or single muscle ﬁbre studies.
As a consequence of this lack of functional data, a recent publication
questioned the description of m.3291T>C as ‘pathogenic’ [8]. The pri-
mary concern of this report was that the mutation affects a nucleotide
position that exhibits poor conservation throughout evolution, and
that only a slight change in the minimum free energy structure of
mt-tRNALeu(UUR) would be predicted. Here we describe another patient
with the m.3291T>C mutation, who presented with bilateral sensori-
neural deafness, and through the study of his muscle biopsy, are able
to conﬁrm the pathogenicity of this mt-tRNA mutation.
2. Case report
A 55 year old male former bus driver with a history of deafness
was referred to Neurology with a 4-year history of falls, speech
disturbance and weight loss. His only medication was Gliclazide for
diabetes mellitus that had been diagnosed two years previously. He
had bilateral sensorineural deafness for 15 years prior to his neuro-
logical presentation for which no explanation had been given, but
hearing aids were of beneﬁt. He neither smoked nor drank alcohol.
He was unaware of any family history of a similar disorder.
Examination revealed macroglossia (Fig. 1A) with associated dys-
arthria, bilateral hearing aids and bilateral pes cavus. He had a prom-
inent dorsocervical fat pad (Fig. 1B) and a lipoma on his posterior
right thigh with an otherwise thin habitus. Muscle bulk was reduced
but without focal wasting or fasciculation. Tone was normal but there
Fig. 1. Clinical assessment. The patient was found to have macroglossia (A) with a fatty inﬁltration as well as a prominent dorsocervical fat pad (B). Cranial sagittal MRI showed
generalised atrophy of the brain and the fatty inﬁltration of the tongue suggestive of a lipoma (C).
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Reﬂexes were suppressed in both upper and lower limbs and plantar
responses were ﬂexor. Sensory testing revealed reduced dorsal
column sensation at the toes and ankles. He had dysmetria of upper
and lower limbs with a broad based gait. He was unable to perform
a tandem gait. Romberg's testing was normal.
Routine blood tests were unremarkable. Cranial MR imaging
showed generalised brain atrophy and fatty inﬁltration of the tongue
(Fig. 1C). CSF was acellular with normal protein and glucose but
a raised CSF lactate of 3.7 mmol/L (normal range, 1.1–2.4 mmol/L).
Very long chain fatty acids, plasma (including CK) and white cell en-
zymes were all normal.
Neurophysiology revealed active denervation in all muscles in the
lower limbs and the right bicep. Those muscles not showing active de-
nervation demonstrated signiﬁcantly reduced recruitment. There were
no changes to support a myopathic or a large ﬁbre neuropathic process.
A tongue biopsy failed to show any evidence of amyloidosis but con-
ﬁrmed fatty inﬁltration consistent with a lipoma. A clinical diagnosis of
mitochondrial disease was made on the basis of a multisystem disorder
involving diabetes, deafness, myopathy, ataxia, mid-line lipomata and
raised CSF lactate. A right tibialis muscle biopsy was performed under
local anaesthetic.
3. Materials and methods
3.1. Muscle histology and histochemistry
Standard histological (H&E, modiﬁed Gomori trichrome staining)
and histochemical (cytochrome c oxidase (COX), succinate dehydro-
genase (SDH) and sequential COX/SDH) analyses of the patient's
muscle biopsy were performed on fresh-frozen skeletal muscle sec-
tions (10 μm), according to established protocols [9].
3.2. Molecular genetic studies
Total DNA was extracted from the patient's whole skeletal muscle
and individual (COX-positive and COX-deﬁcient) skeletal muscle
ﬁbres isolated by laser microcapture as described previously [10],
as well as his asymptomatic sister's blood and urine. Large-scale
mtDNA rearrangements were excluded by long-range PCR [11] before
sequencing of the entire mitochondrial genome was performed using
an ABI 3130xl (Applied Biosystems) system essentially as described
elsewhere [12,13].
3.3. Assessment of m.3291T>C mutation load by quantitative
pyrosequencing
Assessment of mutation load in both whole tissue DNA and DNA
lysates from individual skeletal muscle ﬁbres was performed by
quantitative pyrosequencing. Pyromark Assay Design Software v.2.0(Qiagen) was used to design locus speciﬁc PCR and pyrosequencing
primers, which ampliﬁed a 130 bp PCR product spanning the 3291
nucleotide using a biotinylated forward primer (nt 3224-3245): Bio-5′
GGGTTTGTTAAGATGGCAGAGC 3′ and a reverse primer (nt 3353-3330):
5′ GCGATTAGAATGGGTACAATGAGG 3′.
Pyrosequencing was achieved on the Pyromark Q24 platform
according to the manufacturer's protocol, employing a mutation-
speciﬁc pyrosequencing primer (nt 3312-3293): 5′ GGGTATGTTGTT
AAGAAGAG 3′. Pyromark Q24 software was used to quantify the
m.3291T>C heteroplasmy levels by directly comparing the relevant
peak heights of both wild type and mutant mtDNA at this site [14].
4. Results
4.1. Histology and histochemistry
Histological analyses including modiﬁed Gomori trichrome
(Fig. 2A) and H&E (Fig. 2B) staining revealed a myopathic picture
consisting of dystrophic changes, marked fatty inﬁltrates and ﬁbre
replacement. Subsarcolemmal aggregates of mitochondria, typical
of “ragged-red” ﬁbres, were also observed, and conﬁrmed by SDH
reaction (Fig. 2C). The individual COX reaction showed evidence of
COX-deﬁcient ﬁbres that were more clearly identiﬁed by the sequen-
tial COX/SDH reaction (Fig. 2D). Interestingly, some ﬁbres appear to
show only a partial deﬁciency, with different regions displaying nor-
mal COX activity.
4.2. Molecular genetic investigations
Large-scale rearrangements of the mtDNA genome were excluded
through long-range PCR analysis. Sequencing of the whole mitochon-
drial genome identiﬁed a previously reported m.3291T>C mutation in
theMTTL1 gene which was clearly heteroplasmic (Fig. 3A). Haplogroup
analysis placed this patient into haplogroup K1b1a1, with which the
m.3291T>C mutation has not been associated, whilst searching of the
MitoMap (www.mitomap.org) andmtDB (www.mtdb.igp.uu.se/) data-
bases, and a literature search using PubMed (www.ncbi.nlm.nih.gov/
pubmed), conﬁrmed that it is not a recognised polymorphic variant
[15,1].
The m.3291T>C mutation was shown by pyrosequencing to be
present at heteroplasmic levels in the patient's skeletal muscle (39%
mutation load), and at low levels in both blood (6% mutation load)
and urine (6% mutation load) from his clinically-unaffected sister,
suggestive of maternal transmission.
4.3. Single-ﬁbre segregation studies of the m.3291T>C mutation
Single-ﬁbre pyrosequencing was performed on individual
COX-positive and COX-deﬁcient ﬁbres to investigate whether the
m.3291T>C mutation segregated with respiratory chain deﬁciency.
Fig. 2. Histological and histochemical analyses of the patient's skeletal muscle biopsy. Both modiﬁed Gomori trichrome (A) and joint haemotoxylin and eosin (H&E) stain (B) of the
patient's skeletal muscle showed a dystrophic biopsy with fatty inﬁltrate and sub-sarcolemmal accumulation of mitochondria. COX-deﬁcient ﬁbres were identiﬁed by the individual
cytochrome c oxidase (COX) reaction (C) and the individual succinate dehydrogenase (SDH) reaction (D), whilst sequential COX/SDH histochemistry conﬁrmed the identity of true
COX-deﬁcient ﬁbres (D).
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those exhibiting partial deﬁciency were excluded. The mutation was
found at signiﬁcantly higher levels in COX-deﬁcient ﬁbres (89.1±
9.9%, n=18) compared to COX-positive ﬁbres (51.1±27.1%, n=17),
a statistically signiﬁcant ﬁnding (Pb0.001, two-tailed Student's t test)
(Fig. 3B).
5. Discussion
Here we describe a patient who presented with neck and tongue
lipomas and sensorineural deafness, in whom a previously reported
m.3291T>C mutation in mt-tRNALeu(UUR) was identiﬁed. This
heteroplasmic substitution has previously been linked to a number
of disease presentations, but until now, there has been insufﬁcient
functional evidence to conﬁrm its pathogenicity. The single-ﬁbre
data we have presented here conﬁrms the pathogenicity of this muta-
tion. This report also reafﬁrms the heterogeneity of the genotype:
phenotype relationship of mt-tRNA point mutations, through the
association of m.3291T>C with a new disease phenotype.
The gene for mt-tRNALeu(UUR), MTTL1, is widely acknowledged as
a hotspot for mitochondrial disease-causing point mutations and is
most commonly associated with the MELAS syndrome. Interestingly,
the patient here did not have MELAS, but rather bilateral deafness and
fatty deposits resembling lipomas. Previously, lipomas have been asso-
ciated primarily with the m.8344A>Gmutation in mt-tRNALys [16–18],
although the m.3271T>C mutation has also been linked to lipoma for-
mation [19].
A skeletal muscle biopsy from the patient was found to be highly
dystrophic, with considerable fatty deposits, ragged-red ﬁbres and a
low level of COX-deﬁcient ﬁbres. Unexpectedly, a number of ﬁbres
showed localised COX-deﬁciency, with different regions of the ﬁbre
showing varying degrees of biochemical deﬁciency. The patient's ho-
mogenate skeletal muscle surprisingly had a lower mutation load than
that measured in individual COX-positive ﬁbres, possibly explained bycontamination of the homogenate by the extensive fatty inﬁltrates
observed in the biopsy.
The heteroplasmic m.3291T>C mutation in the T-Loop of
mt-tRNALeu(UUR) (Fig. 3C) was identiﬁed by whole mtDNA sequencing
of skeletal muscle from the patient, whilst maternal transmission was
suggested through the sequencing of blood and urine from his unaf-
fected sister. This mutation has been associated with a variety of mi-
tochondrial disorders in several unrelated patients [2,5–7], however
these reports have yet to provide conclusive proof of pathogenicity
through single-ﬁbre or transmitochondrial cybrid studies. This lack
of supportive data raised doubts regarding the role of this mutation
in causing disease and evidence based primarily on the conserved na-
ture of the affected position has proved insufﬁcient to allay these con-
cerns [8].
As has been observed in a number of cases, including most notably
m.8344A>G [20], pathogenicity is not dependent upon the conserva-
tion or otherwise of the affected base. Although a useful measure of
pathogenicity, as indicated by the fact that over 90% of deﬁnitely
pathogenic mt-tRNA point mutations affect well-conserved positions,
an over-emphasis on evolutionary conservation, compounded by an
inconsistent selection of species for comparison means that relying
on evolutionary conservation to classify mt-tRNA point mutations
as pathogenic is, in the absence of supporting functional evidence,
ﬂawed [21,22].
The data presented here conﬁrms the role of the m.3291T>C mu-
tation in mitochondrial pathogenesis based on the revised mt-tRNA
point mutation pathogenicity scoring system [21]. The mutation has
been reported on several occasions, is heteroplasmic, segregates
with disease and has both histochemical and biochemical evidences
of respiratory chain deﬁciency. The mutation only shows moderate
conservation (Fig. 3D) according to the consensus panel of species
[22], but crucially, this report provides evidence from single-ﬁbre
studies that the mutation segregates with biochemical deﬁciency.
Consequently, this mutation now scores 14 points according to the
Fig. 3.Molecular, genetic and functional investigation of the m.3291T>C mutation. The identiﬁed m.3291T>C mutation is shown in a sequencing chromatogram (A), whilst muta-
tion load analysis in single COX-positive and COX-deﬁcient ﬁbres demonstrated segregation of the mutation with biochemical deﬁciency (B). The m.3291T>C mutation is located in
the T-loop of mt-tRNALeu(UUR) (C), whilst the affected base shows moderate evolutionary conservation across a range of species (D).
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[21].
This investigation has provided conclusive evidence that supports
the pathogenic role of the previously reported m.3291T>C mutation
in human mitochondrial disease. Functional studies are essential for
conﬁrming the pathogenicity of mt-tRNA point mutations, and al-
though indicative, the evolutionary conservation of affected positions
should not be over-valued.
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